vs
六旗（FUN）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
六旗的季度营收约是Pacira BioSciences, Inc.的1.3倍（$225.6M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -119.0%，领先120.7%），六旗同比增速更快（11.7% vs 5.0%）
六旗娱乐是总部位于美国北卡罗来纳州夏洛特的游乐园运营企业，由雪松会与原六旗公司于2024年7月1日对等合并而成，是全球最大的区域性游乐园运营商。旗下共运营42个场地，包含27座游乐园、15座水上乐园，配套9处 onsite 度假物业。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
FUN vs PCRX — 直观对比
营收规模更大
FUN
是对方的1.3倍
$177.4M
营收增速更快
FUN
高出6.7%
5.0%
净利率更高
PCRX
高出120.7%
-119.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $225.6M | $177.4M |
| 净利润 | $-268.6M | $2.9M |
| 毛利率 | — | — |
| 营业利润率 | — | 3.9% |
| 净利率 | -119.0% | 1.6% |
| 营收同比 | 11.7% | 5.0% |
| 净利润同比 | -22.2% | — |
| 每股收益（稀释后） | — | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FUNPCRX
| Q1 26 | $225.6M | $177.4M | ||
| Q4 25 | $650.1M | $196.9M | ||
| Q3 25 | $1.3B | $179.5M | ||
| Q2 25 | $930.4M | $181.1M | ||
| Q1 25 | $202.1M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $1.3B | $168.6M | ||
| Q2 24 | $571.6M | $178.0M |
净利润FUNPCRX
| Q1 26 | $-268.6M | $2.9M | ||
| Q4 25 | $-92.4M | — | ||
| Q3 25 | $-1.2B | $5.4M | ||
| Q2 25 | $-99.6M | $-4.8M | ||
| Q1 25 | $-219.7M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $111.0M | $-143.5M | ||
| Q2 24 | $55.6M | $18.9M |
毛利率FUNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 91.4% | 79.5% | ||
| Q3 25 | 91.6% | 80.9% | ||
| Q2 25 | 91.3% | 77.4% | ||
| Q1 25 | 89.3% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 91.9% | 76.9% | ||
| Q2 24 | 90.7% | 75.1% |
营业利润率FUNPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | -3.8% | 1.2% | ||
| Q3 25 | -83.7% | 3.5% | ||
| Q2 25 | 8.0% | 4.7% | ||
| Q1 25 | -158.9% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 19.5% | -82.8% | ||
| Q2 24 | 21.6% | 15.9% |
净利率FUNPCRX
| Q1 26 | -119.0% | 1.6% | ||
| Q4 25 | -14.2% | — | ||
| Q3 25 | -90.1% | 3.0% | ||
| Q2 25 | -10.7% | -2.7% | ||
| Q1 25 | -108.7% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.2% | -85.1% | ||
| Q2 24 | 9.7% | 10.6% |
每股收益（稀释后）FUNPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.93 | $0.05 | ||
| Q3 25 | $-11.77 | $0.12 | ||
| Q2 25 | $-0.99 | $-0.11 | ||
| Q1 25 | $-2.20 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $1.10 | $-3.11 | ||
| Q2 24 | — | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $116.5M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $279.2M | $653.9M |
| 总资产 | $7.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FUNPCRX
| Q1 26 | $116.5M | $144.3M | ||
| Q4 25 | $91.1M | $238.4M | ||
| Q3 25 | $70.7M | $246.3M | ||
| Q2 25 | $107.4M | $445.9M | ||
| Q1 25 | $61.5M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $89.7M | $453.8M | ||
| Q2 24 | $52.9M | $404.2M |
总债务FUNPCRX
| Q1 26 | — | — | ||
| Q4 25 | $5.2B | $372.2M | ||
| Q3 25 | $5.0B | $376.7M | ||
| Q2 25 | $5.3B | $580.5M | ||
| Q1 25 | $5.0B | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $2.3B | — |
股东权益FUNPCRX
| Q1 26 | $279.2M | $653.9M | ||
| Q4 25 | $549.8M | $693.1M | ||
| Q3 25 | $614.3M | $727.2M | ||
| Q2 25 | $1.8B | $757.8M | ||
| Q1 25 | $1.8B | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $2.3B | $749.6M | ||
| Q2 24 | — | $879.3M |
总资产FUNPCRX
| Q1 26 | $7.7B | $1.2B | ||
| Q4 25 | $7.8B | $1.3B | ||
| Q3 25 | $7.9B | $1.3B | ||
| Q2 25 | $9.5B | $1.5B | ||
| Q1 25 | $9.2B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $9.4B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
负债/权益比FUNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 9.40× | 0.54× | ||
| Q3 25 | 8.16× | 0.52× | ||
| Q2 25 | 2.97× | 0.77× | ||
| Q1 25 | 2.75× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 1.95× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FUN
| In-park admissions revenues | $113.4M | 50% |
| In-park product revenues | $89.0M | 39% |
| Out-of-park revenues | $28.8M | 13% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
